1. Home
  2. ABEO vs LPA Comparison

ABEO vs LPA Comparison

Compare ABEO & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • LPA
  • Stock Information
  • Founded
  • ABEO N/A
  • LPA 2013
  • Country
  • ABEO United States
  • LPA United States
  • Employees
  • ABEO N/A
  • LPA N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • LPA
  • Sector
  • ABEO Health Care
  • LPA
  • Exchange
  • ABEO Nasdaq
  • LPA Nasdaq
  • Market Cap
  • ABEO 277.6M
  • LPA 241.7M
  • IPO Year
  • ABEO 1980
  • LPA N/A
  • Fundamental
  • Price
  • ABEO $5.86
  • LPA $6.19
  • Analyst Decision
  • ABEO Strong Buy
  • LPA
  • Analyst Count
  • ABEO 3
  • LPA 0
  • Target Price
  • ABEO $18.00
  • LPA N/A
  • AVG Volume (30 Days)
  • ABEO 292.3K
  • LPA 38.3K
  • Earning Date
  • ABEO 11-14-2024
  • LPA 11-13-2024
  • Dividend Yield
  • ABEO N/A
  • LPA N/A
  • EPS Growth
  • ABEO N/A
  • LPA N/A
  • EPS
  • ABEO N/A
  • LPA N/A
  • Revenue
  • ABEO N/A
  • LPA $42,725,424.00
  • Revenue This Year
  • ABEO N/A
  • LPA N/A
  • Revenue Next Year
  • ABEO $7,097.06
  • LPA N/A
  • P/E Ratio
  • ABEO N/A
  • LPA N/A
  • Revenue Growth
  • ABEO 147.52
  • LPA 13.12
  • 52 Week Low
  • ABEO $3.05
  • LPA $6.00
  • 52 Week High
  • ABEO $9.01
  • LPA $525.00
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 38.62
  • LPA N/A
  • Support Level
  • ABEO $5.95
  • LPA N/A
  • Resistance Level
  • ABEO $6.78
  • LPA N/A
  • Average True Range (ATR)
  • ABEO 0.32
  • LPA 0.00
  • MACD
  • ABEO -0.07
  • LPA 0.00
  • Stochastic Oscillator
  • ABEO 7.07
  • LPA 0.00

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

Share on Social Networks: